Evidence map›Paper›PMID 41057501›Full record

ArticleCommunications chemistry2025

Exploring the macrocyclic chemical space for heuristic drug design with deep learning models.

Feng Hu, Xiaotong Jia, Wenjie Liao, Ziqi Chen, Hongjie Bi, Huan Ge, Dandan Liu, Rongrong Zhang, Yuting Hu, Wenyi Mei and 5 more

Abstract read
In one paragraph

Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Feng Hu *Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.ORCID http://orcid.org/0009-0008-1654-1246
Xiaotong Jia *Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Wenjie Liao *Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Ziqi ChenShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Hongjie BiShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Huan GeShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Dandan LiuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Rongrong ZhangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Yuting HuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Wenyi MeiShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Zhenjiang ZhaoShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Kai ZhangInnovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai, China. kzhang@cs.ecnu.edu.cn.
Lili ZhuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China. zhulfl@ecust.edu.cn.
Yanyan DiaoInnovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai, China. diaoyan1025@126.com.
Honglin LiShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China. hlli@ecust.edu.cn.ORCID http://orcid.org/0000-0003-2270-1900

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82404517National Natural Science Foundation of China (National Science Foundation of China) 82425104
6 · The paper itself

Abstract

Macrocyclic compounds hold great promise as therapeutic agents. However, their structural optimization remains constrained by the limited availability of bioactive candidates, which in turn hampers the systematic exploration of structure-activity relationships. Here we introduce CycleGPT, a generative chemical language model designed specifically to address these challenges. CycleGPT is characterized by a progressive transfer learning paradigm that incrementally transfers knowledge from pre-trained chemical language models to specialized macrocycle generation, thereby overcoming the data shortage issue. Meanwhile, it adopts an innovative probabilistic sampling strategy that effectively improves the structural novelty of generated macrocycles while ensuring domain-specific adaptability. In a prospective drug design based on CycleGPT and a JAK2 activity prediction model, we successfully developed a new JAK2 drug candidate with a good selectivity profile (inhibiting 17 wild-type kinases) and promising potential for treating polycythemia in vivo, demonstrating the practicality of deep learning methods in macrocyclic drug design.

Identifiers

PMID41057501
PMCPMC12504684

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.